Abstract
The current modifications to licensing procedures still leave a basically flawed system in place. A more radical solution is proposed that involves dispensing with Phase 3 trials and making medicines available at the end of Phase 2 to those who are fully informed of the potential risks and benefits and wish to take part in this novel procedure. The advantages include a shorter development time, lower development costs and allowing smaller companies to take medicines to the clinic. The principal obstacle is that medicines are subject to strict liability rather than the tort of negligence – and this will have to be amended in due course.
Keywords: Phase 3, strict liability.
Reviews on Recent Clinical Trials
Title:A More Radical Solution
Volume: 10 Issue: 1
Author(s): Peter J. Lachmann
Affiliation:
Keywords: Phase 3, strict liability.
Abstract: The current modifications to licensing procedures still leave a basically flawed system in place. A more radical solution is proposed that involves dispensing with Phase 3 trials and making medicines available at the end of Phase 2 to those who are fully informed of the potential risks and benefits and wish to take part in this novel procedure. The advantages include a shorter development time, lower development costs and allowing smaller companies to take medicines to the clinic. The principal obstacle is that medicines are subject to strict liability rather than the tort of negligence – and this will have to be amended in due course.
Export Options
About this article
Cite this article as:
Lachmann J. Peter, A More Radical Solution, Reviews on Recent Clinical Trials 2015; 10 (1) . https://dx.doi.org/10.2174/1574887110666150430151051
DOI https://dx.doi.org/10.2174/1574887110666150430151051 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Applications of Pharmacogenomics to Neurological Disorders
Current Molecular Medicine Cardiovascular Magnetic Resonance Imaging: State of the Art
Current Cardiology Reviews Individual Differences in the Neurobiology of Social Stress: Implications for Depression-Cardiovascular Disease Comorbidity
Current Neuropharmacology Lipoprotein (a) Management: Lifestyle and Hormones
Current Medicinal Chemistry The Role of Brain Gaseous Transmitters in the Regulation of the Circulatory System
Current Pharmaceutical Biotechnology Malnutrition in Patients with End-Stage Renal Disease - Anorexia,Cachexia and Catabolism
Current Nutrition & Food Science The Critical Roles of HSC70 in Physiological and Pathological Processes
Current Pharmaceutical Design Host Pathways of Hemostasis that Regulate Group A Streptococcus pyogenes Pathogenicity
Current Drug Targets Allograft-Induced Proliferation of Vascular Smooth Muscle Cells: Potential Targets for Treating Transplant Vasculopathy
Current Vascular Pharmacology Hypertension and Atrial Fibrillation: Any Change with the New Anticoagulants
Current Pharmaceutical Design Lipoproteins, Stroke and Statins
Current Vascular Pharmacology Semi-Quantitative Ultrasonographic Evaluation of NAFLD
Current Pharmaceutical Design Why and How We Should Treat Elderly Patients with Hypertension?
Current Vascular Pharmacology High-Density Lipoprotein-Mediated Anti-Atherosclerotic and Endothelial-Protective Effects: A Potential Novel Therapeutic Target in Cardiovascular Disease
Current Pharmaceutical Design L-Dopa Related Hyperhomocysteinemia: A Possible Mediator of Toxicity?
Letters in Drug Design & Discovery Acute Cardioembolic Cerebral Infarction: Answers to Clinical Questions
Current Cardiology Reviews Moderate Hyperhomocysteinemia and Immune Activation
Current Pharmaceutical Biotechnology ATP Synthesis Revisited: New Avenues for the Management of Mitochondrial Diseases
Current Pharmaceutical Design The Synthetic and Biological Attributes of Pyrazole Derivatives: A Review
Mini-Reviews in Medicinal Chemistry Inhibition of sPLA2-IIA, C-reactive Protein or Complement: New Therapy for Patients with Acute Myocardial Infarction?
Cardiovascular & Hematological Disorders-Drug Targets